Ikena Oncology Files 2024 10-K, Cites Pionyr Acquisition
Ticker: IMA · Form: 10-K · Filed: Mar 6, 2025 · CIK: 1835579
| Field | Detail |
|---|---|
| Company | Ikena Oncology, INC. (IMA) |
| Form Type | 10-K |
| Filed Date | Mar 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, acquisition, biotech, licensing
Related Tickers: IKNA
TL;DR
IKNA 2024 10-K filed. Key events include Pionyr acquisition in April 2024. Check financials.
AI Summary
Ikena Oncology, Inc. filed its 2024 10-K on March 6, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Boston, MA. Key dates and entities mentioned include the University of Texas at Austin in relation to a license agreement from December 31, 2015, and the acquisition of Pionyr Immunotherapeutics Inc. in April 2024.
Why It Matters
This filing provides a comprehensive overview of Ikena Oncology's financial health and strategic activities for the fiscal year 2024, including significant corporate actions like the acquisition of Pionyr Immunotherapeutics.
Risk Assessment
Risk Level: medium — As a biotechnology company, Ikena Oncology faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Ikena Oncology, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-06 (date) — Filing date
- University of Texas at Austin (company) — Licensor in a license agreement
- 2015-12-31 (date) — Date of license agreement
- Pionyr Immunotherapeutics Inc. (company) — Acquired entity
- 2024-04-01 (date) — Start date of Pionyr acquisition period
FAQ
What was the primary business of Ikena Oncology in 2024?
Ikena Oncology, Inc. is in the Biological Products (No Diagnostic Substances) sector, as indicated by its SIC code [2836].
When was the 10-K filing for the fiscal year ending December 31, 2024, submitted?
The 10-K filing was submitted on March 6, 2025.
Does the filing mention any significant acquisitions or restructurings?
Yes, the filing mentions Pionyr Immunotherapeutics Inc. (ikna:PionyrImmunotherapeuticsIncMember) and Restructuring and Other Charges (ikna:RestructuringAndOtherChargesMember).
Are there any disclosed license agreements with academic institutions?
Yes, there is a mention of a license agreement with the University of Texas at Austin (ikna:UniversityOfTexasAtAustinMember) dated December 31, 2015.
What stock incentive plan is referenced in the filing?
The filing references the Two Thousand And Twenty-One Stock Incentive Plan (ikna:TwoThousandAndTwentyOneStockIncentivePlanMember).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 6, 2025 regarding Ikena Oncology, Inc. (IMA).